

Investor News

Birgit Grund
Senior Vice President
Investor Relations

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Deutschland
T +49 6172 608-2485
F +49 6172 608-2488
birgit.grund@fresenius.com
www.fresenius.com

July 30, 2013

Fresenius announces record results, raises 2013 Group earnings guidance

H1/2013:

- Sales €10.0 billion (+8% at actual rates, +9% in constant currency)
- EBIT¹ €1.4 billion (+1% at actual rates, +2% in constant currency)
- Net income² €482 million (+11% at actual rates, +12% in constant currency)

Ulf Mark Schneider, CEO of Fresenius, said: "The first-half results underline that our broad geographic presence and well-diversified business contribute to the company's success in a challenging environment. We are expanding our footprint in fast-growing emerging markets and work on promising growth initiatives. We remain highly confident of our company's growth prospects and raise 2013 Group earnings guidance."

¹ 2013 excluding one-time integration costs of Fenwal Holdings, Inc. ("Fenwal"). 2012 before one-time items.

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding one-time integration costs of Fenwal. 2012 before one-time items.

2013 Group earnings guidance raised

Based on the Group's positive growth prospects for the second half of 2013, Fresenius raises its full-year earnings guidance. The company now expects net income¹ to increase by 11% to 14% in constant currency. Previously, Fresenius expected net income growth of 7% to 12% in constant currency. The company fully confirms its sales guidance. Sales are expected to increase by 7% to 10% in constant currency.

The Group plans to invest around 5% of sales in property, plant and equipment.

The net debt/EBITDA ratio is projected to be at the lower end of the targeted range of 2.5 to 3.0 by the end of 2013.

Sales growth of 9% in constant currency

Group sales increased by 8% (9% in constant currency) to €9,987 million (H1/2012: €9,236 million). Organic sales growth was 5%. Acquisitions contributed 5%. Divestitures reduced sales growth by 1%. Sales in the business segments developed as follows:

€ in millions	H1/2013	H1/2012	Change at actual rates	Currency translation effects	Change at constant rates	Organic growth	Acquisitions/divestitures	% of total sales
Fresenius Medical Care	5,388	5,150	5%	-1%	6%	5%	1%	54%
Fresenius Kabi	2,519	2,234	13%	-1%	14%	4%	10%	25%
Fresenius Helios	1,695	1,525	11%	0%	11%	5%	6%	17%
Fresenius Vamed	421	348	21%	0%	21%	12%	9%	4%

Organic sales growth was 5% in North America and 2% in Europe. In Latin America (13%) and Africa (30%) organic sales growth was particularly strong. In Asia-Pacific organic sales growth was 7%.

€ in millions	H1/2013	H1/2012	Change at actual rates	Currency translation effects	Change at constant rates	Organic growth	Acquisitions/divestitures	% of total sales
North America	4,268	3,910	9%	-2%	11%	5%	6%	42%
Europe	4,010	3,764	7%	0%	7%	2%	5%	40%
Asia-Pacific	954	884	8%	-1%	9%	7%	2%	10%
Latin America	570	529	8%	-7%	15%	13%	2%	6%
Africa	185	149	24%	-8%	32%	30%	2%	2%
Total	9,987	9,236	8%	-1%	9%	5%	4%	100%

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding one-time integration costs of Fenwal (~ €50 million pre tax). 2012 before one-time items.

Net income growth of 12% in constant currency

Group EBITDA¹ grew by 3% (4% in constant currency) to €1,860 million (H1/2012: €1,806 million). Group EBIT¹ increased by 1% (2% in constant currency) to €1,448 million (H1/2012: €1,440 million). The EBIT margin of 14.5% (H1/2012: 15.6%) was impacted by a margin reduction at Fresenius Medical Care as well as the first-time consolidation of Fenwal. However, Q2/2013 margin of 14.8% already showed a distinct improvement over Q1/2013 (14.2%).

Group net interest remained at last year's level of -€313 million, including €14 million one-time costs resulting from the early redemption of the Senior Notes originally due 2016.

The Group tax rate¹ improved to 28.5% (H1/2012: 30.8%).

Noncontrolling interest was €330 million (H1/2012: €346 million), of which 94% was attributable to the noncontrolling interest in Fresenius Medical Care.

Group net income² increased by 11% (12% in constant currency) to €482 million (H1/2012: €434 million). Earnings per share² increased by 5% to €2.70 (H1/2012: €2.58).

In H1/2013, the weighted average number of shares outstanding was 178,306,694 (H1/2012: 167,986,059).

Group net income attributable to shareholders of Fresenius SE & Co. KGaA including one-time integration costs for Fenwal was €462 million or €2.59 per share.

Continued investment in growth

The Fresenius Group spent €425 million on property, plant and equipment (H1/2012: €388 million). Acquisition spending was €150 million (H1/2012: €2,097 million).

Cash flow development

Operating cash flow was €947 million (H1/2012: €1,136 million). The decrease relates primarily to a one-time payment by Fresenius Medical Care regarding the amendment of the supply agreement for the iron product Venofer in North America. In H1/2012, the operating cash flow was positively influenced by extraordinary payments on trade accounts receivable. The cash flow margin reached 9.5% (H1/2012: 12.3%). Net capital expenditure increased to €416 million (H1/2012: €358 million). Free cash flow before acquisitions and dividends was €531 million (H1/2012: €778 million). Free cash flow after acquisitions and dividends increased to €92 million (H1/2012: -€1,154 million).

¹ 2013 excluding one-time integration costs of Fenwal; 2012 before one-time items.

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding one-time integration costs of Fenwal. 2012 before one-time items.

Solid balance sheet structure

The Group's total assets increased by 1% (1% in constant currency) to €30,973 million (Dec. 31, 2012: €30,664 million). Current assets grew by 2% to €8,257 million (Dec. 31, 2012: €8,113 million). Non-current assets increased by 1% to €22,716 million (Dec. 31, 2012: €22,551 million).

Total shareholders' equity increased by 2% to €12,955 million (Dec. 31, 2012: €12,758 million). The equity ratio was 41.8% (Dec. 31, 2012: 41.6%).

Group debt was €11,204 million (Dec. 31, 2012: €11,028 million). Net debt was €10,362 million (Dec. 31, 2012: €10,143 million). As of June 30, 2013, the net debt/EBITDA ratio was 2.63¹ (Dec. 31, 2012: 2.56²).

Number of employees increases

As of June 30, 2013, the Fresenius Group increased the number of its employees by 2% to 173,325 (Dec. 31, 2012: 169,324).

Fresenius Biotech

Fresenius Biotech's sales were €16.6 million (H1/2012: €16.6 million). The EBIT was -€6 million (H1/2012: -€11 million).

With effect of 28 June 2013, Fresenius sold Fresenius Biotech to the Fuhrer family, owners of Neopharm, Israel's second-largest pharmaceutical company. The transaction resulted in a negligible book gain and will have a positive effect on Group earnings, as the projected H2/2013 EBIT loss of ~€10 million will now not materialize.

¹ Pro forma including Fenwal; before one-time costs (non-financing expenses) related to the takeover offer to RHÖN-KLINIKUM AG shareholders, one-time costs at Fresenius Medical Care and one-time integration costs of Fenwal.

² Pro forma including Damp Group, Liberty Dialysis Holdings, Inc. and Fenwal; before one-time costs (non-financing expenses) related to the takeover offer to RHÖN-KLINIKUM AG shareholders, and one-time costs at Fresenius Medical Care.

Business Segments

Fresenius Medical Care

Fresenius Medical Care is the world's leading provider of services and products for patients with chronic kidney failure. As of June 30, 2013, Fresenius Medical Care was treating 264,290 patients in 3,212 dialysis clinics.

US\$ in millions	H1/2013	H1/2012	Change
Sales	7,076	6,677	6%
EBITDA	1,353	1,386	-2%
EBIT	1,038	1,092	-5%
Net income ¹	488	520	-6%
Employees (Jun 30/Dec 31)	92,749	90,866	2%

- **Strong organic sales growth of 5%**
- **Excellent operating cash flow margin of 11.9%**
- **2013 guidance confirmed**

Sales increased by 6% (6% in constant currency) to US\$7,076 million (H1/2012: US\$6,677 million). Organic sales growth was 5%. Acquisitions contributed a further 3%. Divestitures reduced sales growth by 2%.

Sales in dialysis services increased by 7% (7% in constant currency) to US\$5,421 million (H1/2012: US\$5,082 million). Dialysis product sales grew by 4% (4% in constant currency) to US\$1,655 million (H1/2012: US\$1,594 million).

In North America, sales grew 7% to US\$4,663 million (H1/2012: US\$4,353 million). Dialysis services sales grew by 8% to US\$4,261 million (H1/2012: US\$3,960 million). Dialysis product sales increased by 2% to US\$402 million (H1 2012: US\$393 million).

Sales outside North America ("International" segment) grew by 4% (5% in constant currency) to US\$2,397 million (H1/2012: US\$2,307 million). Sales in dialysis services increased by 3% to US\$1,161 million (H1/2012: US\$1,122 million). Dialysis product sales grew by 4% to US\$1,236 million (H1/2012: US\$1,185 million).

EBIT decreased by 5% to US\$1,038 million (H1/2012: US\$1,092 million).

Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA decreased by 6% to US\$488 million (H1/2012¹: US\$520 million).

¹ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA; 2012 adjusted for a non-taxable investment gain of US\$140 million.

The operating cash flow was US\$841 million (H1/2012: US\$932 million). The reduction relates to an one-time payment regarding the amendment of the agreement for the iron product Venofer in North America (US\$100 million). The cash flow margin was 11.9% (H1/2012: 14.0%).

Fresenius Medical Care expects revenue to grow to more than US\$14.6 billion in 2013. In April 2013 general budget cuts in the U.S. (sequestration) were effectively introduced. The company does not assume that these will be revised this year. Therefore, the net income guidance range has been confirmed and has been substantiated for the potential impact from sequestration on the company's business performance. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between US\$1.1 billion and US\$1.15 billion in 2013.

For further information, please see Fresenius Medical Care's Investor News at www.fmc-ag.com.

Fresenius Kabi

Fresenius Kabi offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.

€ in millions	H1/2013 ¹	H1/2012	Change
Sales	2,519	2,234	13%
EBITDA	575	530	8%
EBIT	469	452	4%
Net income ²	242	210	15%
Employees (Jun 30/Dec 31)	31,002	30,214	3%

- **Organic sales growth of 4% on the back of strong H1/12**
- **EBIT margin excluding Fenwal at the upper end of guidance**
- **2013 guidance fully confirmed**

Sales increased by 13% (14% in constant currency) to €2,519 million (H1/2012: €2,234 million). Organic sales growth was 4%. Acquisitions contributed 11%, while divestitures reduced sales growth by 1%.

Sales in Europe grew by 6% (organic growth: 2%) to €1,030 million (H1/2012: €974 million). Sales in North America increased by 29% to €784 million (H1/2012: €609 million), primarily driven by the consolidation of Fenwal. Organic growth was 6%. In Asia-Pacific sales increased by 10% (organic growth: 6%) to €456 million (H1/2012: €415 million). Sales in Latin America/Africa increased by 6% (organic growth: 9%) to €249 million (H1/2012: €236 million). Growth in H1/2013 comes over an exceptionally strong H1/2012 base, posting 9% organic sales growth in North America, 6% in Europe, 15% in Asia-Pacific and 14% in Latin America/Africa.

EBIT¹ grew by 4% to €469 million (H1/2012: €452 million). EBIT includes one-time charges of €24 million to remediate manufacturing issues following FDA audits at the Grand Island, USA, and Kalyani, India, facilities. The EBIT margin was 18.6%. Excluding Fenwal, the EBIT margin of 19.8% (H1/2012: 20.2%) was at the upper end of the full-year guidance.

Net income² increased by 15% to €242 million (H1/2012: €210 million).

Fresenius Kabi's operating cash flow was €238 million (H1/2012: €288 million). Last year's operating cash flow was positively influenced by extraordinary payments on trade accounts receivable. The cash flow margin was 9.4% (H1/2012: 12.9%). Cash flow before acquisitions and dividends was €120 million (H1/2012: €199 million).

¹ Excluding Fenwal integration costs.

² Net income attributable to shareholders of Fresenius Kabi AG.

The integration of Fenwal progressed as planned with related one-time costs of €27 million pre-tax.

Fresenius Kabi fully confirms its outlook for 2013 and projects sales growth of 12% to 14% in constant currency. Organic sales growth is expected in the range of 3% to 5%.

The company projects an EBIT margin of 19% to 20% excluding Fenwal and of 18% to 19% including Fenwal. EBIT in constant currency is expected to exceed 2012 EBIT. The guidance includes expected one-time charges to remediate manufacturing issues following FDA audits at the Grand Island, USA, and Kalyani, India, facilities. It also includes a gain related to the sale of the respiratory homecare business in France.

Fresenius Kabi guidance excludes Fenwal integration costs (~€50 million pre tax); also see Group guidance.

Fresenius Helios

Fresenius Helios is one of the largest private hospital operators in Germany. HELIOS owns 74 hospitals, thereof 51 acute care clinics including six maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal and 23 post-acute care clinics. HELIOS treats more than 2.9 million patients per year, thereof more than 780,000 inpatients, and operates more than 23,000 beds.

€ in millions	H1/2013	H1/2012 ¹	Change
Sales	1,695	1,525	11%
EBITDA	235	201	17%
EBIT	179	150	19%
Net income ²	119	91	31%
Employees (Jun 30/Dec 31)	42,590	42,881	-1%

- **Strong organic sales growth of 5%**
- **EBIT margin up 80 basis points to 10.6%**
- **2013 earnings guidance raised – EBIT between €370 million and €395 million**

Sales increased by 11% to €1,695 million (H1/2012: €1,525 million). Organic sales growth was 5%, acquisitions contributed 7%. Divestitures reduced sales growth by 1%.

EBIT grew by 19% to €179 million (H1/2012: €150 million). The EBIT margin increased to 10.6% (H1/2012: 9.8%).

Net income² increased by 31% to €119 million (H1/2012: €91 million).

Sales of the established hospitals grew by 5% to €1,588 million. EBIT improved by 15% to €175 million. The EBIT margin increased to 11.0% (H1/2012: 10.0%). Sales of the acquired hospitals (consolidation <1 year) were €107 million, EBIT was €4 million.

Fresenius Helios raises its 2013 full-year guidance to reflect the additional funding for German hospitals that will have a positive effect starting in August, 2013. The company now projects EBIT of €370 million to €395 million. Previously, it expected to reach an EBIT of €360 million to €380 million. Fresenius Helios fully confirms its sales outlook and projects organic sales growth of 3% to 5%.

¹ Adjusted for post-acute care clinic Zihlschlacht transferred to Fresenius Vamed.

² Net income attributable to shareholders of HELIOS Kliniken GmbH.

Fresenius Vamed

Fresenius Vamed offers engineering and services for hospitals and other health care facilities.

€ in millions	H1/2013	H1/2012 ¹	Change
Sales	421	348	21%
EBITDA	19	18	6%
EBIT	15	14	7%
Net income ²	9	10	-10%
Employees (Jun 30/Dec 31)	6,222	4,432	40%

- **Excellent organic sales growth of 12% at upper end of guidance**
- **Largest single turnkey project order in company history received**
- **2013 guidance fully confirmed**

Sales increased by 21% to €421 million (H1/2012: €348 million). Organic sales growth was 12%, acquisitions contributed 9%. Sales in the project business increased by 13% to €208 million (H1/2012: €184 million). Sales in the service business grew by 30% to €213 million (H1/2012: €164 million).

EBIT was €15 million (H1/2012: €14 million). The EBIT margin reached 3.6% (H1/2012: 4.0%).

Net income² was €9 million (H1/2012: €10 million).

Order intake increased to €311 million (H1/2012: €156 million). Fresenius Vamed received the largest single order in its history for a turnkey construction of an acute-care hospital in Austria, with a total volume of €173 million. As of June 30, 2013, the company's order backlog was €1,089 million (Dec. 31, 2012: €987 million).

Fresenius Vamed fully confirms its outlook for 2013 and expects to achieve sales growth of 8% to 12%. EBIT growth is projected in the range of 5% to 10%.

¹ Adjusted for post-acute care clinic Zihlschlacht transferred from Fresenius Helios to Fresenius Vamed.

² Net income attributable to shareholders of Vamed AG.

Analyst-/Investor Conference Call

As part of the publication of the results for the first half of 2013, a conference call will be held on July 30, 2013 at 2 p.m. CEST (8 a.m. EDT). All investors are cordially invited to follow the conference call in a live broadcast via the Internet at www.fresenius.com, see Investor Relations, Presentations. Following the call, a replay of the conference call will be available on our website.

#

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2012, Group sales were €19.3 billion. On June 30, 2013, the Fresenius Group had 173,325 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

Fresenius Group Figures

Statement of Comprehensive Income (U.S. GAAP, unaudited)

€ in millions	Q2/2013	Q2/2012	H1/2013	H1/2012
Sales	5,097	4,817	9,987	9,236
Costs of sales	-3,505	-3,232	-6,867	-6,212
Gross profit	1,592	1,585	3,120	3,024
Selling, general and administrative expenses	-770	-744	-1,532	-1,451
Research and development expenses	-90	-69	-167	-140
Operating income (EBIT)	732	772	1,421	1,433
Investment gain	0	11	0	108
Interest result	-150	-166	-313	-313
Other financial result	0	-29	0	-29
Financial result	-150	-184	-313	-234
Income before income taxes	582	588	1,108	1,199
Income taxes	-163	-181	-316	-337
Net income	419	407	792	862
Less noncontrolling interest	-176	-195	-330	-420
Net income attributable to Fresenius SE & Co. KGaA¹	258	234	482	434
Net income attributable to Fresenius SE & Co. KGaA	243	212	462	442
Earnings per ordinary share (€)¹	1.44	1.35	2.70	2.58
Fully diluted earnings per ordinary share (€) ¹	1.44	1.34	2.68	2.55
Earnings per ordinary share (€)	1.36	1.22	2.59	2.63
Fully diluted earnings per ordinary share (€)	1.34	1.21	2.56	2.60
Average number of shares	178,377,232	172,669,401	178,306,694	167,986,059
EBITDA¹	962	968	1,860	1,806
Depreciation and amortization	210	189	412	366
EBIT¹	752	779	1,448	1,440
EBITDA margin	18.9%	20.1%	18.6%	19.6%
EBIT margin	14.8%	16.2%	14.5%	15.6%

¹ 2013 excludes one-time integration costs of Fenwal; 2012 before one-time items.

Reconciliation according to U.S. GAAP (unaudited)

The Group's U.S. GAAP financial results as of June 30, 2013 and June 30, 2012 comprise special items. Net income attributable to shareholders of Fresenius SE & Co. KGaA in the first half of 2013 excludes one-time integration costs of Fenwal; 2012 before a non-taxable investment gain at Fresenius Medical Care as well as one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG. Adjusted earnings represent the Group's business operations in the reporting period.

H1 2013/2012

€ in millions	H1/2013 before special items	one-time integration costs of Fenwal	H1/2013 according to U.S. GAAP	H1/2012 before special items	non-taxable investment gain at Fresenius Medical Care	one-time costs related to the takeover offer to the shareholders of RHÖN- KLINIKUM AG	H1/2012 according to U.S. GAAP
Sales	9,987		9,987	9,236			9,236
EBIT	1,448	-27	1,421	1,440		-7	1,433
Investment gain	0		0	0	108		108
Interest result	-313		-313	-313			-313
Other financial result	0		0	0		-29	-29
Net income before taxes	1,135	-27	1,108	1,127	108	-36	1,199
Income taxes	-323	7	-316	-347		10	-337
Net income	812	-20	792	780	108	-26	862
Less noncontrolling interest	-330		-330	-346	-74		-420
Net income attributable to shareholders of Fresenius SE & Co. KGaA	482	-20	462	434	34	-26	442

Q2 2013/2012

€ in millions	Q2/2013 before special items	one-time integration costs of Fenwal	Q2/2013 according to U.S. GAAP	Q2/2012 before special items	non-taxable investment gain at Fresenius Medical Care	one-time costs related to the takeover offer to the shareholders of RHÖN- KLINIKUM AG	Q2/2012 according to U.S. GAAP
Sales	5,097		5,097	4,817			4,817
EBIT	752	-20	732	779		-7	772
Investment gain	0		0	0	11		11
Interest result	-150		-150	-166			-166
Other financial result	0		0	0		-29	-29
Net income before taxes	602	-20	582	613	11	-36	588
Income taxes	-168	5	-163	-191		10	-181
Net income	434	-15	419	422	11	-26	407
Less noncontrolling interest	-176		-176	-188	-7		-195
Net income attributable to shareholders of Fresenius SE & Co. KGaA	258	-15	243	234	4	-26	212

Statement of Financial Position (U.S. GAAP, unaudited)

€ in millions	June 30, 2013	Dec. 31, 2012	Change
Assets			
Current assets	8,257	8,113	2%
thereof trade accounts receivable	3,712	3,650	2%
thereof inventories	1,997	1,840	9%
thereof cash and cash equivalents	842	885	-5%
Non-current assets	22,716	22,551	1%
thereof property, plant and equipment	4,966	4,918	1%
thereof goodwill and other intangible assets	16,410	16,298	1%
Total assets	30,973	30,664	1%
Liabilities and shareholders' equity			
Liabilities	17,602	17,508	1%
thereof trade accounts payable	839	961	-13%
thereof accruals and other short-term liabilities	4,569	4,534	1%
thereof debt	11,204	11,028	2%
Noncontrolling interest subject to put provisions	416	398	5%
Noncontrolling interest	5,144	5,125	0%
Total Fresenius SE & Co. KGaA shareholders' equity	7,811	7,633	2%
Total shareholders' equity	12,955	12,758	2%
Total liabilities and shareholders' equity	30,973	30,664	1%

Statement of Cash Flows (U.S. GAAP, unaudited)

€ in millions	H1/2013	H1/2012	Change
Net income	792	862	-8%
Depreciation and amortization	412	366	13%
Change in accruals for pensions	24	17	41%
Cash flow	1,228	1,245	-1%
Change in working capital	-281	-109	-158%
Operating cash flow	947	1,136	-17%
Capital expenditure, net	-416	-358	-16%
Cash flow before acquisitions and dividends	531	778	-32%
Cash used for acquisitions, net	7	-1,558	100%
Dividends paid	-446	-374	-19%
Free cash flow after acquisitions and dividends	92	-1,154	108%
Financial investments	0	-952	100%
Cash provided by/used for financing activities	-133	2,474	-105%
Effect of exchange rates on change in cash and cash equivalents	-2	12	-117%
Net change in cash and cash equivalents	-43	380	-111%

Segment reporting by business segment H1 2013 (U.S. GAAP, unaudited)

€ in millions	Fresenius Medical Care			Fresenius Kabi			Fresenius Helios			Fresenius Vamed			Corporate/Other			Fresenius Group		
	H1/2013	H1/2012 ³	Change	H1/2013 ⁴	H1/2012	Change	H1/2013	H1/2012	Change	H1/2013	H1/2012	Change	H1/2013 ⁵	H1/2012 ⁶	Change	H1/2013	H1/2012	Change
Sales	5,388	5,150	5%	2,519	2,234	13%	1,695	1,525	11%	421	348	21%	-36	-21	-71%	9,987	9,236	8%
thereof contribution to consolidated sales	5,376	5,140	5%	2,497	2,209	13%	1,695	1,525	11%	404	348	16%	15	14	7%	9,987	9,236	8%
thereof intercompany sales	12	10	20%	22	25	-12%	0	0		17	-	--	-51	-35	-46%	0	0	
contribution to consolidated sales	54%	55%		25%	24%		17%	17%		4%	4%		0%	0%		100%	100%	
EBITDA	1,030	1,069	-4%	575	530	8%	235	201	17%	19	18	6%	-26	-19	-37%	1,833	1,799	2%
Depreciation and amortization	240	227	6%	106	78	36%	56	51	10%	4	4	0%	6	6	0%	412	366	13%
EBIT	790	842	-6%	469	452	4%	179	150	19%	15	14	7%	-32	-25	-28%	1,421	1,433	-1%
Net interest	-158	-157	-1%	-130	-142	8%	-27	-33	18%	-1	-	--	3	19	-84%	-313	-313	0%
Income taxes	-208	-239	13%	-84	-84	0%	-29	-22	-32%	-4	-4	0%	9	12	-25%	-316	-337	6%
Net income attributable to shareholders of Fresenius SE & Co. KGaA	372	401	-7%	242	210	15%	119	91	31%	9	10	-10%	-280	-270	-4%	462	442	5%
Operating cash flow	640	719	-11%	238	288	-17%	80	79	1%	3	58	-95%	-14	-8	-75%	947	1,136	-17%
Cash flow before acquisitions and dividends	397	508	-22%	120	199	-40%	34	31	10%	-2	54	-104%	-18	-14	-29%	531	778	-32%
Total assets¹	17,071	16,921	1%	8,718	8,662	1%	4,472	4,408	1%	730	676	8%	-18	-3	--	30,973	30,664	1%
Debt¹	6,381	6,290	1%	4,933	4,964	-1%	1,341	1,293	4%	122	74	65%	-1,573	-1,593	1%	11,204	11,028	2%
Capital expenditure	254	214	19%	111	118	-6%	50	46	9%	5	4	25%	5	6	-17%	425	388	10%
Acquisitions / Financial Investments²	86	1,304	-93%	55	6	--	5	562	-99%	6	21	-71%	-2	1,156	-100%	150	3,049	-95%
Research and development expenses	47	43	9%	117	88	33%	-	-	--	0	0		3	9	-67%	167	140	19%
Employees (per capita on balance sheet date)¹	92,749	90,866	2%	31,002	30,214	3%	42,590	42,881	-1%	6,222	4,432	40%	762	931	-18%	173,325	169,324	2%
Key figures																		
EBITDA margin	19.1%	20.8%		22.8%	23.7%		13.9%	13.2%		4.5%	5.2%					18.6% ⁴	19.6% ⁸	
EBIT margin	14.7%	16.4%		18.6%	20.2%		10.6%	9.8%		3.6%	4.0%					14.5% ⁴	15.6% ⁸	
Depreciation and amortization in % of sales	4.5%	4.4%		4.2%	3.5%		3.3%	3.3%		1.0%	1.1%					4.1%	4.0%	
Operating cash flow in % of sales	11.8%	14.0%		9.4%	12.9%		4.7%	5.2%		0.7%	16.7%					9.5%	12.3%	
ROOA ¹	11.0%	11.4%		12.2%	12.3%		8.6%	8.2%		11.8%	12.8%					10.6% ⁷	11.0% ⁹	

¹ 2012: December 31

² Includes an investment of cash in the amount of €952 million by Fresenius SE & Co. KGaA in the second quarter of 2012

³ Excluding special item from the acquisition of Liberty Dialysis Holdings, Inc.

⁴ Excluding one-time integration costs of Fenwal Holdings, Inc.

⁵ Including one-time integration costs of Fenwal Holdings, Inc.

⁶ Including special item from the acquisition of Liberty Dialysis Holdings, Inc. and one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG

⁷ The underlying pro forma EBIT does not include one-time integration costs of Fenwal Holdings, Inc., one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofor contract and the donation to the American Society of Nephrology.

⁸ Before one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG

⁹ The underlying pro forma EBIT does not include one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG, special items from the renegotiation of the Venofor contract and the donation to the American Society of Nephrology.

Segment reporting by business segment Q2 2013 (U.S. GAAP, unaudited)

€ in millions	Fresenius Medical Care			Fresenius Kabi			Fresenius Helios			Fresenius Vamed			Corporate/Other			Fresenius Group		
	Q2/2013	Q2/2012 ²	Change	Q2/2013 ³	Q2/2012	Change	Q2/2013	Q2/2012	Change	Q2/2013	Q2/2012	Change	Q2/2013 ⁴	Q2/2012 ⁵	Change	Q2/2013	Q2/2012	Change
Sales	2,765	2,672	3%	1,259	1,142	10%	854	815	5%	237	199	19%	-18	-11	-64%	5,097	4,817	6%
thereof contribution to consolidated sales	2,758	2,666	3%	1,248	1,129	11%	854	815	5%	229	199	15%	8	8	0%	5,097	4,817	6%
thereof intercompany sales	7	6	17%	11	13	-15%	0	0		8	-	--	-26	-19	-37%	0	0	
contribution to consolidated sales	54%	55%		25%	24%		17%	17%		4%	4%		0%	0%		100%	100%	
EBITDA	538	576	-7%	287	276	4%	121	109	11%	12	11	9%	-16	-11	-45%	942	961	-2%
Depreciation and amortization	122	118	3%	55	39	41%	29	27	7%	2	2	0%	2	3	-33%	210	189	11%
EBIT	416	458	-9%	232	237	-2%	92	82	12%	10	9	11%	-18	-14	-29%	732	772	-5%
Net interest	-79	-82	4%	-64	-73	12%	-12	-19	37%	0	-	--	5	8	-38%	-150	-166	10%
Income taxes	-110	-134	18%	-39	-44	11%	-15	-12	-25%	-3	-3	0%	4	12	-67%	-163	-181	10%
Net income attributable to shareholders of Fresenius SE & Co. KGaA	201	215	-7%	123	112	10%	63	50	26%	6	6	0%	-150	-171	12%	243	212	15%
Operating cash flow	401	352	14%	106	195	-46%	47	45	4%	-42	13	--	-9	-7	-29%	503	598	-16%
Cash flow before acquisitions and dividends	269	234	15%	44	142	-69%	20	16	25%	-46	10	--	-12	-10	-20%	275	392	-30%
Capital expenditure	142	119	19%	66	85	-22%	30	26	15%	4	3	33%	4	4	0%	246	237	4%
Acquisitions / Financial Investments¹	29	38	-24%	42	2	--	2	19	-89%	-1	21	-105%	-1	1,042	-100%	71	1,122	-94%
Research and development expenses	24	21	14%	64	43	49%	-	-	--	0	0		2	5	-60%	90	69	30%
Key figures																		
EBITDA margin	19.5%	21.6%		22.8%	24.2%		14.2%	13.4%		5.1%	5.5%					18.9% ³	20.1% ⁴	
EBIT margin	15.1%	17.2%		18.4%	20.8%		10.8%	10.1%		4.2%	4.5%					14.8% ³	16.2% ⁴	
Depreciation and amortization in % of sales	4.4%	4.4%		4.4%	3.4%		3.4%	3.3%		0.8%	1.0%					4.1%	3.9%	
Operating cash flow in % of sales	14.6%	13.2%		8.4%	17.1%		5.5%	5.5%		-17.7%	6.5%					9.9%	12.4%	

¹ Includes an investment of cash in the amount of €952 million by Fresenius SE & Co. KGaA in the second quarter of 2012

² Excluding special item from the acquisition of Liberty Dialysis Holdings, Inc.

³ Excluding one-time integration costs of Fenwal Holdings, Inc.

⁴ Including one-time integration costs of Fenwal Holdings, Inc.

⁵ Including special item from the acquisition of Liberty Dialysis Holdings, Inc. and one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG

⁶ Before one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG